YOLFTbeta
08

Biotoxtech Co. Ltd

086040 · KQ · Healthcare / Biotechnology & Medical Research

2,390.00KRW+50.00 (+2.14%)

Price History

Full chart

Market Stats

Previous Close2,340.00
Open2,340.00
Day Range2,325.00 – 2,395.00
52-Week Range1,896.00 – 4,115.00
Volume17.77K
Market Cap34.89B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.60
50-Day Avg2,294.00
200-Day Avg2,680.98

About

Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and business consulting and vicegerent of nonclinical trial activities. The company's safety evaluation research field includes general toxicity studies, carcinogenicity studies, local toxicity studies, reproductive and developmental studies, genotoxicity studies, immunotoxicity studies, safety pharmacology, ecotoxicology studies, histopathology/clinical pathology, and juvenile animal toxicity studies. Biotoxtech Co., Ltd. was founded in 2000 and is headquartered in Cheongwon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology & Medical Research
  • CEOMr. Jong-Koo Kang Ph.D.
  • Employees208
  • Headquarters53, Yeongudanji-ro, Cheongwon, South Korea, 28115, Korea
  • Websitehttps://www.biotoxtech.com

Leadership

  • Mr. Jong-Koo Kang Ph.D.Chief Exec. Officer · b. 1955
  • Sung-Jin BaekSales Director and Director · b. 1969
  • Yong-Bae ParkManaging Director · b. 1964
  • Sang-Gu LeeHead of Research Center and Director · b. 1960

Financials

Income Statement

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue23.09B17.72B17.27B15.09B16.68B22.26B25.56B27.25B25.85B26.43B32.72B37.29B32.63B41.34B47.02B
Growth (%)--23.27%-2.51%-12.65%+10.53%+33.46%+14.86%+6.57%-5.11%+2.22%+23.80%+13.98%-12.50%+26.69%+13.73%
Cost of Revenue12.24B11.79B12.26B11.76B13.63B14.88B16.44B19.57B20.48B19.99B22.17B24.81B30.73B38.78B41.14B
Gross Profit---1.63B3.05B7.37B9.12B7.67B5.37B6.44B10.55B12.48B1.90B2.56B5.88B
Gross Margin---10.81%18.28%33.13%35.68%28.16%20.77%24.35%32.23%33.47%5.82%6.19%12.51%
Operating Expense---6.28B7.34B5.35B6.94B7.60B5.50B5.90B5.91B11.50B10.12B11.07B10.69B
Operating Income5.21B255.00M--4.65B-4.30B2.03B2.19B70.62M-130.82M537.46M4.63B979.25M-8.22B-8.52B-4.81B
Operating Margin22.57%1.44%--30.80%-25.76%9.11%8.55%0.26%-0.51%2.03%14.16%2.63%-25.20%-20.60%-10.23%
EBITDA-----------3.32B-4.39B362.90M9.41B
EBITDA Margin-----------8.89%-13.45%0.88%20.02%
Net Income3.27B1.35B--4.53B-3.91B1.04B1.39B3.62B-1.58B2.61B7.11B2.73B-4.88B-6.43B1.16B
Net Income Margin14.18%7.63%--30.01%-23.42%4.69%5.44%13.30%-6.12%9.89%21.74%7.31%-14.95%-15.55%2.47%
R&D--1.35B1.11B23.30M82.80M82.80M202.63M----453.68M694.43M642.58M
R&D as % of Total Revenue--7.81%7.37%0.14%0.37%0.32%0.74%----1.39%1.68%1.37%
Interest Expense00000000542.17M444.15M834.51M2.02B3.76B5.09B5.42B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.10%1.68%2.55%5.40%11.54%12.30%11.54%

Balance Sheet

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets44.19B44.68B46.29B47.84B45.38B48.01B59.77B63.14B60.18B63.65B90.74B125.70B147.04B136.19B131.61B
Total Liabilities22.45B18.75B20.69B21.15B21.79B23.47B33.18B31.88B29.98B30.13B49.60B81.47B98.80B96.11B99.68B
Total Equity19.97B24.37B24.01B25.96B22.67B24.54B26.59B31.25B30.19B33.53B41.14B44.23B51.71B40.08B40.16B
Cash3.74B4.23B6.87B7.74B5.81B10.62B7.06B6.22B5.37B2.75B238.00K1.40M27.48B11.37B18.63B
Total Debt------15.30B16.76B16.61B12.33B-----
Net Debt---------14.23B8.16B36.15B33.75B51.45B43.65B

Cash Flow

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow3.28B1.63B--2.05B-798.17M5.28B6.02B3.06B1.44B4.56B4.35B-1.31B-16.24B-7.12B6.64B
Investing Cash Flow----4.34B-624.36M-386.31M-11.51B-5.74B-2.87B-7.01B-7.76B-26.40B-1.98B-9.84B-
Financing Cash Flow-1.45B3.30B6.33B-611.88M-227.04M2.17B1.74B567.86M-141.21M19.28B21.93B33.02B762.48M-
Capital Expenditure2.96B1.85B666.71M302.94M496.36M491.52M3.41B2.32B449.34M1.37B7.62B30.79B4.88B2.38B2.23B
Free Cash Flow---------2.02B-3.61B-32.09B-21.12B-9.50B4.40B
FCF to OCF---------44.34%-83.06%2451.65%130.07%133.44%66.36%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015May 13, 2016Aug 16, 2016Nov 9, 2016Feb 22, 2017Apr 24, 2017Aug 14, 2017Nov 13, 2017Mar 22, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 21, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 27, 2020Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------21.7150.7721.78-------------------------------
EPS Actual-37.33150.01149.39172.54144.06-215.5440.6046.05209.9191.96-49.3197.33112.54-70.8210.2179.5062.20-5.47-43.94-19.79-105.97-48.28-100.78-128.00-89.04-40.69-25.52-119.12-16.4824.4328.2136.2821.1450.7738.37-13.92264.00-29.00143.00-126.51-27.98-136.84-88.19144.37-16.37127.0536.2032.5747.8062.01134.54241.9618.3421.93188.54-42.62-51.33-151.61-108.43-5.90-81.16-114.82-75.42-134.30-93.99-66.46317.83-118.66-121.46-377.06
Surprise------------------------------------1116.03%-157.12%556.57%-------------------------------
Timing----------------------------Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--------------------------

Key Statistics & Ratios

Market Cap34.89B
Enterprise Value73.61B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.66
Price / Book1.06
Revenue (TTM)37.63B
Gross Profit (TTM)11.87B
EBITDA4.37B
Profit Margin18.31%
Operating Margin7.25%
Return on Equity-1484.56%
Return on Assets1.70%
Shares Outstanding14.56M
Shares Float10.68M
Beta0.60
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 25, 2014539:500